Videos

There are a number of ongoing clinical trials testing psychedelics as a treatment for psychiatric disorders.

Costello suggests low intensity exercise for those coming off of COVID-19 infections.

For World Breastfeeding Week, a lactation consultant explains Montefiore's care team strategies and guidance to expecting and new mothers.

Brett King, MD, PhD, encourages dermatologists to wait for more clinical data before making any assumptions on the drug class' safety and selectivity.

Fecal microbiota transplantation could be crucial in the coming years in treating C difficile infections.

Brett King, MD, PhD, compares the efficacy of JAKs with biologics in the atopic dermatitis setting.

Brett King, MD, PhD, provides an overview of JAK inhibitors and their interaction with the JAK-STAT pathway.

In this series of HCPLive® State of the Science, 4 experts discuss knowledge and treatment in the cardiovascular risk management space.

Dr. Mazzocchi talks of the promising new cancer care therapies and how to properly inform and care for patients with cancer who may be overwhelmed.

A recent study has found statins are underutilized for NASH and NAFLD patients.

A leading author of a recent Oxford study speaks of azithromycin, its limitations in treating patients with COVID-19, and the importance of properly utilizing the antibiotic.

Roughly 60% of participants in the SINUS-24 and SINUS-52 trials reported improvements in the severity of loss-of-taste.

Dr. Jorge Maspero speaks of the complications of severe chronic rhinosinusitis with nasal polyps and how dupilumab could improve the daily struggles patients face.

Marc Bonaca, MD, discusses a new analysis of the VOYAGER PAD trial and implications for patients with diabetes and CLI.

Dr. Robert Baillieu discusses how the COVID-19 pandemic has specifically impacted patients dealing with addiction problems.

It could take up to 10 years to develop new treatments for inflammatory bowel disease.

Andres Yarur, MD, of the Medical College of Wisconsin, comments on the chronic, progressive nature of ulcerative colitis and highlights special considerations for classifying patients based on disease severity.

A large proportion of IBS-C patients did not seek health care during the COVID-19 pandemic despite symptoms.

COVID-19 patients with liver injuries are at a higher risk of mortality or lengthier hospital stays.

C difficile and sepsis infections can be especially difficult to treat.

There is a substantial health care cost for CDI patients with sepsis.

A survey at ACC 2021 showed 38% of cardiology professionals were burnt out during COVID-19. What factors in the field have already made it difficult to cope?

The high-risk patient population is under-represented in new research and agents. Why characteristics set it apart from other cardiovascular diseases?

New data suggest 90 days following an initial ACS event is the greatest time of likelihood for another high-risk event. How can this inform cardiovascular research?

Marc Bonaca, MD, explains the value of new assessments made in the pivotal peripheral artery disease clinical trial.